Cite
HARVARD Citation
Glen, H. et al. (n.d.). 432 Correlative analyses of serum biomarkers and clinical outcomes in the phase 2 study of lenvatinib, everolimus, and the combination, in patients with metastatic renal cell carcinoma following 1 VEGF-targeted therapy. European journal of cancer. pp. S89-. [Online].